Genetic Signature of Aggressive Ovarian, Endometrial Cancers Unraveled at Yale

Genetic Signature of Aggressive Ovarian, Endometrial Cancers Unraveled at Yale
Carcinosarcomas are rare, highly aggressive tumors associated with very poor outcomes. Recently, researchers at Yale University School of Medicine shed light on the genetic signature of uterine and ovarian carcinosarcomas, which could influence the development of better treatments. The study, "Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial–mesenchymal transition," was published in Proceeding of the National Academy of Sciences (PNAS). Endometrial and ovarian cancers are the most prevalent gynecologic tumors in women with an estimated 82,330 new cases per year in the United States alone, according to the National Cancer Institute. This year, the NIS predicts that the cancers could lead to 24,710 deaths. Although carcinosarcomas represent only 2 to 5 percent of all gynecologic cancers, and 1 to 2 percent of ovarian cancers, its high biologic aggressiveness and resistance to standard chemotherapy and radiation therapies lead to the disproportionate number of deaths. Carcinosarcomas are characterized by having features of carcinoma (common of epithelial cancers like breast, lung, or prostate), and sarcoma (observed in blood cancers and bone or muscle cancers). Given poor prognosis and lack of consensus regarding the origin of the cancers, the Yale researchers sought to examine the genetic landscape of carcinosarcomas with hope to determine the molecular basis of the tumor's aggressive behavior and to identify new therapeutic targets. Using extensive g
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *